SarahNoonbergMDPhD

Hospital Medicine/Hospitalist

Chief Medical Officer, Maze Therapeutics

Dr. Noonberg is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
331 Oyster Point Blvd
South San Francisco, CA 94080
Phone+1 415-319-0314

PubMed

151 citations
Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.
David E. Geller, Michael W. Konstan, Jeffrey Smith, Sarah B. Noonberg, Carol Conrad
Pediatric Pulmonology. 2007-04-01
7 citations
Small-molecule inhibition of glycogen synthase 1 for the treatment of Pompe disease and other glycogen storage disorders.
Julie C Ullman, Kevin T Mellem, Yannan Xi, Vyas Ramanan, Hanne Merritt
Science Translational Medicine. 2024-01-17
61 citations
The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostat...
Christopher P. Evans, Celestia S. Higano, Thomas E. Keane, Gerald L. Andriole, Fred Saad
European Urology. 2016-10-01

Maze Therapeutics Reveals Its Initial Three Lead Programs Targeting Underlying Genetic Drivers of Life-Threatening DiseasesMarch 23rd, 2021
Maze Therapeutics Expands Experienced Management Team with Appointment of Sarah Noonberg, M.D., Ph.D., as Chief Medical OfficerOctober 6th, 2020
Nohla Therapeutics Announces Hiring of Dr. Sarah Noonberg as Chief Medical Officer and Appointment of Dr. Colleen Delaney as Chief Scientific OfficerJuly 30th, 2018
Join now to see all